Chronimed suspends Quick Check shipments:
This article was originally published in Clinica
Executive Summary
Chronimed has suspended all shipments of its Quick Check reagent strip in the US because of unresolved issues with its supplier, Diagnostic Solutions, and the FDA. Chronimed has started negotiations to acquire the manufacturing rights of the strip test from Diagnostic Solutions. The company, based in Minneapolis, Minnesota, must also resolve questions the FDA has about inconsistent strip test results before shipments can resume.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.